Mersana Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$480.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Mersana Therapeutics's estimated annual revenue is currently $43k per year.(i)
  • Mersana Therapeutics received $33.0M in venture funding in June 2016.
  • Mersana Therapeutics's estimated revenue per employee is $193
  • Mersana Therapeutics's total funding is $480.6M.
  • Mersana Therapeutics's current valuation is $451.6M. (January 2022}

Employee Data

  • Mersana Therapeutics has 223 Employees.(i)
  • Mersana Therapeutics grew their employee count by 42% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug's chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana's ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today's cancer treatments.

keywords:N/A

$480.6M

Total Funding

223

Number of Employees

$43k

Revenue (est)

42%

Employee Growth %

$451.6M

Valuation

N/A

Accelerator

Mersana Therapeutics News

2016-06-16 - Mersana Therapeutics Raises $33M Series C Led by Wellington Management

CAMBRIDGE, Mass., June 16, 2016 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Fleximer® technology, today announced the completion of a $33 million Series C fina ...

2016-06-16 - Biotech Company Mersana Therapeutics Closes $33M Series C Financing

Mersana Therapeutics, Inc., a Cambridge, MA-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs), completed a $33m Series C financing. The round was led by new investor Wellington Management Company with participation from new investors ...

2020-04-08 - Mersana Therapeutics Raises $65 Million

CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced th ...

20-Aug-19 - Mersana Therapeutics Announces Initiation of Expansion ...

Mersana Therapeutics Announces Initiation of Expansion Study of XMT-1536 in Patients with Platinum-Resistant Ovarian Cancer and ...

28-Aug-19 - Mersana Therapeutics to Present at Upcoming Investor ...

CAMBRIDGE, Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (MRSN) a clinical-stage biopharmaceutical company ...

12-Sep-19 - Mersana Therapeutics Inc (NASDAQ:MRSN) Given ...

Mersana Therapeutics Inc (NASDAQ:MRSN) has been given a consensus rating of “Buy” by the eight research firms that are presently covering ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$51.7M22415%N/A
#2
$81.2M2251%N/A
#3
$80.4M22513%N/A
#4
$34.8M226-5%N/A
#5
$43.7M2272%N/A

Mersana Therapeutics Funding

DateAmountRoundLead InvestorsReference
2008-10-27$4.0MUndisclosedArticle
2012-08-01$27.0MA-1New Enterprise AssociatesArticle
2013-10-15$5.0MUndisclosedArticle
2014-04-10$14.5MAArticle
2015-03-03$35.0MB-1New Enterprise AssociatesArticle
2016-06-17$33.0MCWellington Management CompanyArticle